Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Kichul | - |
dc.contributor.author | Baek, Han Joo | - |
dc.contributor.author | Kang, Young Mo | - |
dc.contributor.author | Cha, Hoon-Suk | - |
dc.contributor.author | Kang, Seong Wook | - |
dc.contributor.author | Park, Sung-Hwan | - |
dc.contributor.author | Jun, Jae-Bum | - |
dc.contributor.author | Lee, Yun Jong | - |
dc.contributor.author | Choi, In Ah | - |
dc.contributor.author | Song, Yeong Wook | - |
dc.date.accessioned | 2021-08-02T11:30:14Z | - |
dc.date.available | 2021-08-02T11:30:14Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-06 | - |
dc.identifier.issn | 1756-1841 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/13464 | - |
dc.description.abstract | Aim To investigate the efficacy and safety of tacrolimus (TAC) versus leflunomide (LEF) when combined with methotrexate (MTX) in rheumatoid arthritis (RA) patients. Method This was a 24-week multi-center, double-blind, randomized, non-inferiority study targeting RA patients with moderate to severe Disease Activity Score of 28 joints (DAS28 > 3.2) who showed inadequate response to MTX. Patients were randomized into TAC or LEF (add-on to MTX) groups. Initial daily doses of TAC and LEF were 1.5 and 10 mg, respectively, for 4 weeks and then doubled until the end of the study. The primary endpoint was DAS28 comparison at 24 weeks. Results Eighty-seven patients were screened in 10 centers and 75 patients were randomized into two groups. Baseline demographics were comparable between TAC + MTX and LEF + MTX groups. The TAC + MTX group was non-inferior to the LEF + MTX group in terms of DAS28 at 24 weeks (mean difference of DAS28: -0.1812, 95% confidence interval: -0.8073, 0.4450). There was a greater number of adverse events in the LEF + MTX group (66 in LEF + MTX and 49 in TAC + MTX). Six patients presented with transaminitis in the LEF + MTX group compared with two patients in the TAC + MTX group. Conclusion The efficacy of TAC combined with MTX was non-inferior to LEF + MTX. It had a reasonable safety profile in RA patients with moderate to severe disease activity (; KCT0000781). | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jun, Jae-Bum | - |
dc.identifier.doi | 10.1111/1756-185X.13521 | - |
dc.identifier.scopusid | 2-s2.0-85062974126 | - |
dc.identifier.wosid | 000475450300022 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, v.22, no.6, pp.1115 - 1122 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.citation.volume | 22 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1115 | - |
dc.citation.endPage | 1122 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | CYCLOSPORINE | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | SULFASALAZINE | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | 6-MONTH | - |
dc.subject.keywordAuthor | methotrexate | - |
dc.subject.keywordAuthor | non-inferiority | - |
dc.subject.keywordAuthor | rheumatoid arthritis | - |
dc.subject.keywordAuthor | tacrolimus | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.13521 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.